Compass Pathways Plc (NASDAQ:CMPS) announced its first-quarter earnings, reporting a loss of 30 cents per share, which was better than the consensus estimate of a 34 cent-loss. The company's research and development expenses decreased to $26.5 million, down from $30.9 million in the same quarter last year, primarily due to lower costs associated with its Phase 3 COMP360 psilocybin therapy program for treatment-resistant depression. As of March 31, Compass had $466 million in cash and cash equivalents, a significant increase from $149.6 million at the end of 2025. However, debt rose to $50.5 million from $31.6 million. The company has successfully strengthened its cash position through financing and warrant exercises, extending its cash runway into 2028. The FDA granted a rolling submission for the New Drug Application (NDA) for COMP360, with a final submission expected in the fourth quarter of this year. Following the positive earnings report, Compass shares surged by 12.59%, reaching $10.55.